Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00506350

Enrollment

350

Registered

2007-07-25

Start date

2007-08-01

Completion date

2009-10-12

Last updated

2017-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Brief summary

The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate vaccine. Fifty new subjects who did not participate in a primary study (106750, NCT00309634) will be recruited. This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT00309634)

Detailed description

Interventions

BIOLOGICALPandemic influenza candidate vaccine (GSK1562902A) - 1 dose

A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.

BIOLOGICALPandemic influenza candidate vaccine (GSK1562902A) - 2 doses

Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 61 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * For previously primed subjects: participation in the primary study (NCT00309634). * For unprimed subjects: male or female between and including, 19 and 61 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.

Exclusion criteria

* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * For unprimed subjects who did not participate in the primary study (NCT00309634): Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Planned administration/ administration of a licenced vaccine not foreseen by the study protocol within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) of the first dose of vaccine(s). * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * Applicable for control group only: previous vaccination with a pandemic candidate vaccine or a vaccine containing the investigational vaccine adjuvant. * History of hypersensitivity to vaccines. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). * Major congenital defects or serious chronic illness. * History of any neurological disorders or seizures. * Acute disease at the time of enrolment. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination. * Any condition which, in the opinion of the investigator, prevents the subject from participation in the study. * Lactating female. * History of chronic alcohol consumption and/or drug abuse

Design outcomes

Primary

Measure	Time frame	Description
Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	At Day 0	Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.
Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	At Day 21	Seroconversion rate for HI antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	At Day 21	Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.
Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	At Day 0	A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses	Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses	Assessed solicited general symptoms were arthralgia, fatigue, headache, myalgia, shivering, sweating and fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	During the 21-day (Days 0-20) follow-up period after the first vaccination and 30-day (Days 0-29) follow-up period after the second vaccination	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Number of Subjects With Serious Adverse Events (SAEs)	During the entire study period (From Day 0 up to Month 24)	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Secondary

Measure	Time frame	Description
Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	At Days 0, 21 (post-vaccination one) and 42 (post-vaccination two)	Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005. No subject from GSK1562902A AD F1 Primed Group has received a second vaccination.
Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	At Days 0 and 21	Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed wwere H5N1 A/Indonesia and H5N1 A/Vietnam.
Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	At Months 6, 12, 18 and 24	Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005.
Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	At Days 0, 7, 14, 21, 28, 35 and 42	Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.
Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	At Months 6, 12, 18 and 24	Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.
Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	At Days 7,14, 21, 35 and 42	Seroconversion (SCR) was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.
Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	At Days 21 (post-vaccination one) and 42 (post-vaccination two)	Seroconversion rate for anti-HA antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer \< 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.
Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	At Days 7, 14, 21, 35 and 42	Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.
Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	At Days 0, 7, 14, 21, 28, 35 and 42	Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection. The flu strain assessed was A/Indonesia/05/2005 (H5N1).

Countries

Belgium

Participant flow

Participants by arm

Arm	Count
GSK1562902A Non-AD F1 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.	36
GSK1562902A Non-AD F2 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.	40
GSK1562902A Non-AD F3 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.	37
GSK1562902A Non-AD F4 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.	36
Control Group Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.	50
GSK1562902A AD F1 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.	40
GSK1562902A AD F2 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.	35
GSK1562902A AD F3 Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.	41
GSK1562902A AD Approved F Primed Group Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.	35
Total	350

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008
Overall Study	Adverse Event	0	0	0	0	0	0	0	1	1
Overall Study	Lost to Follow-up	1	1	1	1	2	1	0	0	2
Overall Study	Medical Reason	0	0	0	0	1	0	0	0	0
Overall Study	Other	1	1	3	0	3	0	0	2	2
Overall Study	Protocol Violation	0	0	1	0	0	0	1	0	0
Overall Study	Serious Adverse Event	1	0	0	0	0	0	0	0	0
Overall Study	Withdrawal by Subject	0	1	1	1	4	1	1	2	0

Baseline characteristics

Characteristic	GSK1562902A Non-AD F1 Primed Group	GSK1562902A Non-AD F2 Primed Group	GSK1562902A Non-AD F3 Primed Group	GSK1562902A Non-AD F4 Primed Group	Control Group	GSK1562902A AD F1 Primed Group	GSK1562902A AD F2 Primed Group	GSK1562902A AD F3 Primed Group	GSK1562902A AD Approved F Primed Group	Total
Age, Continuous	36.3 Years STANDARD_DEVIATION 12.8	36.3 Years STANDARD_DEVIATION 12.36	36.8 Years STANDARD_DEVIATION 12.87	39.5 Years STANDARD_DEVIATION 13.27	32.1 Years STANDARD_DEVIATION 9.96	38.5 Years STANDARD_DEVIATION 13.43	38.3 Years STANDARD_DEVIATION 14.61	34.8 Years STANDARD_DEVIATION 14.57	35.9 Years STANDARD_DEVIATION 12.78	36.32 Years STANDARD_DEVIATION 12.97
Race/Ethnicity, Customized Race Other	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	4 Participants
Race/Ethnicity, Customized Race White - Arabic / North African heritage	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Race White - Caucasian / European heritage	36 Participants	38 Participants	37 Participants	36 Participants	48 Participants	40 Participants	34 Participants	41 Participants	35 Participants	345 Participants
Sex: Female, Male Female	18 Participants	19 Participants	16 Participants	21 Participants	34 Participants	27 Participants	18 Participants	23 Participants	18 Participants	194 Participants
Sex: Female, Male Male	18 Participants	21 Participants	21 Participants	15 Participants	16 Participants	13 Participants	17 Participants	18 Participants	17 Participants	156 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk
deaths Total, all-cause mortality	0 / 36	0 / 40	0 / 37	0 / 36	0 / 50	0 / 40	0 / 35	1 / 41	1 / 35
other Total, other adverse events	34 / 36	40 / 40	33 / 37	35 / 36	48 / 50	39 / 40	34 / 35	41 / 41	33 / 35
serious Total, serious adverse events	4 / 36	3 / 40	2 / 37	0 / 36	4 / 50	2 / 40	1 / 35	4 / 41	3 / 35

Outcome results

Primary

Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion rate for HI antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.

Time frame: At Day 21

Population: The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	36 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	33 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	34 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	31 Participants

Primary

Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Day 0

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	0 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	1 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	0 Participants

Primary

Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

A seroprotected subject was defined as a vaccinated subject with a serum HI titer equal to or above (≥) 1:40. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Day 21

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	36 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	33 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	34 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	31 Participants

Primary

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were ecchymosis, induration, pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 ecchymosis/induration/redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.

Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	33 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	4 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	34 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	6 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	28 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	36 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	35 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	30 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	2 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	32 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	24 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	32 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	6 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	34 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	28 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	35 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	1 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	45 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	2 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	6 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	47 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	1 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	2 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	6 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	3 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	5 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	4 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	1 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	3 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	1 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	42 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	3 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	1 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
Control Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	38 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	38 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	34 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	34 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	39 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	39 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Across doses	31 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 2	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Dose 1	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Across doses	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Redness, Dose 1	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Pain, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Redness, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Pain, Dose 1	31 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Induration, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Dose 1	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Swelling, Across doses	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Ecchymosis, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Grade 3 Swelling, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Induration, Across doses	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Any Ecchymosis, Across doses	0 Participants

Primary

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, headache, myalgia, shivering, sweating and fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as causally related to the study vaccination. No subject from GSK1562902A AD F1 Primed Group has received Dose 2.

Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available and who had their symptom sheets filled in.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	17 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	17 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	18 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	10 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	11 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	20 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	4 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	6 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	7 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	4 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	6 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	7 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	13 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	14 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	13 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	3 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	10 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	11 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	17 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	10 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	11 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	14 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	20 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	4 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	7 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	2 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	12 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	15 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	17 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	18 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	20 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	16 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	12 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	7 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	18 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	21 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	15 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	8 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	11 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	17 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	15 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	3 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	8 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	2 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	12 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	15 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	8 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	12 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	11 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	9 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	14 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	14 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	14 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	15 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	9 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	2 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	9 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	15 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	15 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	20 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	20 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	7 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	11 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	7 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	14 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	6 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	6 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	6 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	15 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	7 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	12 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	14 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	14 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	15 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	5 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	3 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	18 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	24 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	4 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	1 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	7 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	24 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	22 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	9 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	14 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	3 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	11 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	17 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	7 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	6 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	10 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	6 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	10 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	10 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	25 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	4 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	4 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	23 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	3 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	19 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	24 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	22 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	14 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	1 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	14 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	10 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	1 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	10 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	14 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	13 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	30 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	5 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	29 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	4 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	28 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	4 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	22 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	30 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	2 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	28 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	20 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	3 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	19 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	13 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	6 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	15 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	11 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	19 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	6 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	11 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	16 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	12 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	15 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	16 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	19 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	15 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	9 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	15 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	12 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	10 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	11 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	12 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	5 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	11 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	6 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	9 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	11 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	18 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	11 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	2 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	4 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	9 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	6 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	11 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	10 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	10 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	3 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	11 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	2 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	9 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	18 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Across doses	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 1	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 1	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Across doses	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Across doses	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Across doses	12 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 1	10 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Across doses	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Across doses	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Myalgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Shivering, Dose 1	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fatigue, Dose 1	12 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Dose 1	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 1	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Arthralgia, Across doses	5 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Myalgia, Across doses	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Across doses	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Dose 1	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Headache, Across doses	9 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fatigue, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Sweating, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Myalgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Fever, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Across doses	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Headache, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Fever, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Any Fatigue, Dose 1	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Sweating, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Shivering, Dose 1	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Across doses	8 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Dose 2	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Sweating, Dose 1	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 1	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Headache, Dose 1	8 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Shivering, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Grade 3 Arthralgia, Across doses	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Related Arthralgia, Dose 2	0 Participants

Primary

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame: During the 30-day (Days 0-29) follow-up period after the first vaccination

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	5 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	3 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	13 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	17 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	5 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	17 Participants

Primary

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Time frame: During the 21-day (Days 0-20) follow-up period after the first vaccination and 30-day (Days 0-29) follow-up period after the second vaccination

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	22 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	4 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	24 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	21 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	4 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	26 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	3 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Grade 3 AE(s)	6 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Any AE(s)	33 Participants
Control Group	Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)	Related AE(s)	8 Participants

Primary

Number of Subjects With Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame: During the entire study period (From Day 0 up to Month 24)

Population: The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	2 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	1 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	0 Participants
Control Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	3 Participants
Control Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
Control Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	0 Participants
Control Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	1 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
GSK1562902A AD F1 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	0 Participants
GSK1562902A AD F2 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	1 Participants
GSK1562902A AD F3 Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	1 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 12 - Month 18	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 6 - Month 12	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Month 18 - Month 24	2 Participants
GSK1562902A AD Approved F Primed Group	Number of Subjects With Serious Adverse Events (SAEs)	Day 0 - Month 6	0 Participants

Primary

Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Day 21

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	79.9 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	76.5 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	39.1 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	76.9 Fold increase

Primary

Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Day 21

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	406.8 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	429.5 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	208.4 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	347.9 Titers

Primary

Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Day 0

Population: The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.

Arm	Measure	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	5.1 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	5.6 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	5.3 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	5.2 Titers

Secondary

Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines

Among cytokines expressed after background reduction were cluster of differentiation 4 all doubles (CD4 all doubles), cluster of differentiation 40-ligand (CD40-L), interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α). The flu strains assessed were H5N1 A/Indonesia and H5N1 A/Vietnam.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (MEDIAN)
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 6	1575.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 6	1454.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 12	1183.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 18	1042.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 18	1173.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 24	1220.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 24	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 6	1710.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 6	1605.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 6	1724.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 6	1481.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 6	794.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 6	876.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 6	1152.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 6	1279.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 12	1333.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 12	1171.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 12	1119.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 12	1090.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 12	1290.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 12	746.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 12	670.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 12	1065.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 12	945.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 18	1421.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 18	1536.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 18	1369.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 18	1523.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 18	1316.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 18	1346.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 18	906.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 18	1074.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 24	1307.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 24	1229.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 24	1195.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 24	1146.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 24	1101.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 24	848.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 24	838.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 24	1062.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 24	999.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 6	59.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 6	85.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 6	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 6	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 6	52.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 6	93.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 6	29.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 6	48.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 6	52.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 6	73.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 12	78.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 12	69.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 12	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 12	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 12	56.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 12	55.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 12	46.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 12	77.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 12	54.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 12	55.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 18	35.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 18	48.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 18	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 18	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 18	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 18	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 18	38.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 18	48.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 18	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 18	38.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 24	78.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 24	29.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 24	26.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 24	21.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 24	1.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 24	64.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 24	31.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 24	26.00 T-cell/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 24	37.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 12	95.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 6	1244.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 18	66.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 18	65.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 12	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 18	43.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 24	773.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 24	704.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 24	914.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 24	680.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 18	82.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 18	729.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 18	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 12	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 24	26.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 6	79.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 24	850.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 18	40.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 6	1138.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 6	139.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 24	73.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 6	1190.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 18	946.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 12	54.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 6	1124.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 24	917.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 6	1136.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 6	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 18	743.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 6	1070.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 24	57.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 6	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 6	636.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 18	82.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 12	49.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 6	679.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 24	826.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 6	54.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 6	920.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 18	811.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 24	45.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 6	941.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 6	77.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 12	60.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 12	786.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 24	867.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 18	62.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 12	796.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 6	49.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 24	73.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 12	647.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 24	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 12	54.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 12	641.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 18	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 6	117.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 12	721.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 24	839.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 12	733.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 18	933.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 24	73.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 12	432.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 6	71.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 12	62.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 12	497.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 18	793.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 18	81.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 12	551.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 6	123.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 24	1.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 12	616.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 24	654.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 12	75.50 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 18	1052.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 18	1036.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 12	73.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 18	1022.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 24	25.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 24	93.00 T-cell/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 18	1013.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 12	1100.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 18	1288.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 18	40.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 18	1170.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 18	1062.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 18	865.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 18	965.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 18	1035.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 18	119.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 18	1079.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 24	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 24	1306.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 24	1322.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 24	1280.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 18	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 24	1356.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 24	1105.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 24	1253.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 18	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 24	860.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 24	888.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 18	30.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 24	1023.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 24	32.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 6	89.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 6	107.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 18	47.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 6	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 6	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 18	31.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 6	53.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 24	31.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 6	63.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 6	44.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 18	119.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 6	61.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 24	55.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 6	76.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 6	80.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 18	42.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 12	30.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 12	31.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 12	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 24	65.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 24	1186.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 18	107.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Month 24	102.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 24	102.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 6	1817.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Month 12	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 6	1775.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 6	1720.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 6	1748.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 6	1736.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Month 12	5.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Month 6	1580.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Month 24	65.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 6	929.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 6	885.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Month 12	13.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 6	1467.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 24	64.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 6	1292.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 12	1332.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Month 12	1.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 12	1225.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 12	1159.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Month 12	1134.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Month 12	32.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Month 12	1219.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Month 18	1330.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Month 12	618.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Month 12	643.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Month 12	23.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Month 12	997.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Month 12	939.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Month 18	1392.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Month 12	31.50 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Month 18	1367.00 T-cell/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Month 24	1.00 T-cell/million cells

Secondary

Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines

Time frame: At Days 0 and 21

Arm	Measure	Group	Value (MEDIAN)
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 0	42.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 0	407.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 0	682.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 21	785.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 0	490.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 21	1.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 0	470.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 0	71.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 0	1.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 21	960.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 0	80.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 21	1.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 0	544.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 21	1870.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 0	1.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 21	1187.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 21	150.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 21	166.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 21	1874.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 0	159.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 21	1360.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 0	709.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 21	132.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 0	152.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 0	650.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 0	743.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 21	132.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 21	1842.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 21	1607.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 0	92.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 0	641.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 0	98.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 21	86.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 21	1616.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 21	1945.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 0	59.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 0	599.50 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 21	115.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 21	31.00 T-cells/million cells
GSK1562902A AD F1 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 21	124.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 21	39.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 0	1.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 21	127.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 0	1370.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 21	2504.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 0	1284.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 21	2640.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 0	1363.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 21	2480.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 0	1288.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 21	2652.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 0	1186.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 21	2291.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 0	1195.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 21	2210.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 0	607.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 21	1304.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 0	729.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 21	1105.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 0	944.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 21	1905.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 0	952.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 21	1888.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 0	60.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 21	75.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 0	99.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 21	153.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 21	1.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 0	1.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 21	1.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 0	40.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 0	48.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 21	90.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 0	40.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 21	56.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 0	76.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 0	47.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 21	75.50 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 0	83.00 T-cells/million cells
GSK1562902A AD F2 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 21	98.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 21	2607.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 0	1.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 21	993.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 0	71.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Vietnam, Day 21	1.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 21	2368.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 0	28.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 0	30.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Vietnam, Day 0	473.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Vietnam, Day 0	540.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Indonesia, Day 21	39.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 21	2485.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 21	2721.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 0	51.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 IL-2 - H5N1 A/Indonesia, Day 0	433.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Indonesia, Day 0	357.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 IL-2 - H5N1 A/Vietnam, Day 21	86.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 21	2580.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Indonesia, Day 21	36.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 0	37.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Vietnam, Day 0	525.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 ALL DOUBLES - H5N1 A/Indonesia, Day 0	473.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Indonesia, Day 21	41.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 21	2633.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 0	47.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 21	1616.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 TNF-α - H5N1 A/Vietnam, Day 21	136.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Indonesia, Day 21	52.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Vietnam, Day 0	357.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 0	97.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 0	90.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 21	1658.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 CD40L - H5N1 A/Indonesia, Day 0	457.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 ALL DOUBLES - H5N1 A/Vietnam, Day 21	147.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 TNF-α - H5N1 A/Indonesia, Day 0	294.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 0	1.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 21	1057.50 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 INF-γ - H5N1 A/Vietnam, Day 21	149.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD8 CD40L - H5N1 A/Indonesia, Day 21	1.00 T-cells/million cells
GSK1562902A AD F3 Primed Group	Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines	CD4 INF-γ - H5N1 A/Vietnam, Day 0	406.50 T-cells/million cells

Secondary

Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion (SCR) was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.

Time frame: At Days 7,14, 21, 35 and 42

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	21 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	19 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	12 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	27 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	33 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	17 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	28 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	34 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	19 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	18 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	19 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	23 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	23 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	23 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	27 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	21 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	17 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	27 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	48 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	12 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	0 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	29 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	49 Participants

Secondary

Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer\< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Indonesia/05/2005.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	8 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	7 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	12 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	12 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	12 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	5 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	13 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	17 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	17 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	7 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	15 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	15 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	3 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	14 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	19 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	5 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	15 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	5 Participants
Control Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	16 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	26 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	18 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	27 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	21 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	16 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	24 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	20 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	24 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	16 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	20 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	27 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	22 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	21 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	23 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	24 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	11 Participants

Secondary

Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion rate for anti-HA antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer \< 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.

Time frame: At Days 21 (post-vaccination one) and 42 (post-vaccination two)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	29 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	31 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	35 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	44 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	49 Participants

Secondary

Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion rate for neutralizing antibody response was defined as the percentage of vaccines who have either a pre-vaccination titer \< 1:40 and a post-vaccination titer ≥ 1:56 or a pre-vaccination titer ≥ 1:56 and at least a 4-fold increase in post-vaccination titer.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	29 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	17 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	21 Participants
GSK1562902A AD F1 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	13 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	13 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	29 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	19 Participants
GSK1562902A AD F2 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	14 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	29 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	41 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	35 Participants
GSK1562902A AD F3 Primed Group	Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	44 Participants

Secondary

Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroprotection rate was defined as the percentage of vaccines with a serum HI antibody titer ≥ 1:40 that usually is accepted as indicating protection. The flu strain assessed was A/Indonesia/05/2005 (H5N1).

Time frame: At Days 0, 7, 14, 21, 28, 35 and 42

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	12 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	0 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	21 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	19 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	34 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	0 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	17 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	28 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	27 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	32 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	33 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	19 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	23 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	19 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	22 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	0 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	23 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	18 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	17 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	21 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	26 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	0 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	27 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	27 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	23 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	48 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	49 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	0 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	29 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	12 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	0 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	49 Participants

Secondary

Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	12 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	8 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	12 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	7 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	13 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	5 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	12 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	17 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	15 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	15 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	7 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	17 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	19 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	14 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	13 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	3 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	5 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	15 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	16 Participants
Control Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	5 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	22 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	27 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	19 Participants
GSK1562902A AD F1 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	28 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	25 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	16 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	25 Participants
GSK1562902A AD F2 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	20 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	22 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	20 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	27 Participants
GSK1562902A AD F3 Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	16 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	24 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	21 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	11 Participants
GSK1562902A AD Approved F Primed Group	Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	23 Participants

Secondary

Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Days 7, 14, 21, 35 and 42

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	7.4 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	11.0 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	4.3 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	10.6 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	9.1 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	24.0 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	13.2 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	5.1 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	11.5 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	23.3 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	13.2 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	12.7 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	5.5 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	9.8 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	8.4 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	32.0 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	15.4 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	7.5 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	28.3 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	14.3 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	88.6 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	1.0 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	6.2 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	112.7 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	2.7 Fold increase

Secondary

Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion factor (SCF) was defined as the fold increase in H5N1 HI antibody GMTs post-vaccination compared to Day 0. The flu strains assessed were A/Indonesia/05/2005.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	3.4 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	3.8 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	2.6 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	1.9 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	1.8 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	3.3 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	3.3 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	4.6 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	4.5 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	1.9 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	4.1 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	3.7 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	4.9 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	3.8 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	6.7 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	1.7 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	2.4 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	3.2 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	3.6 Fold increase
Control Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	2.2 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	6.9 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	15.0 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	10.1 Fold increase
GSK1562902A AD F1 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	18.3 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	11.5 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	18.3 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	5.9 Fold increase
GSK1562902A AD F2 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	14.1 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	11.2 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	4.1 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	7.9 Fold increase
GSK1562902A AD F3 Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	7.9 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	9.8 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	4.7 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	11.6 Fold increase
GSK1562902A AD Approved F Primed Group	Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	13.6 Fold increase

Secondary

Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Days 0, 7, 14, 21, 28, 35 and 42

Population: The analysis was performed on the ATP cohort for immunogenicity, whiich included all evaluable subjects for whom immunogenicity data and assay results for antibodies against at least one study vaccine antigen component after vaccination were available.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	48.1 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	38.0 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	5.1 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	54.3 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	22.1 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	56.0 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	46.6 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	79.3 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	25.3 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	57.6 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	66.1 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	5.0 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	116.3 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	119.9 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	42.2 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	49.1 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	5.0 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	27.7 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	56.0 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	65.8 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	63.7 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	71.5 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	128.0 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	37.6 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	141.4 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	160.0 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	5.0 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	77.1 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 14	13.7 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	443.0 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 35	563.6 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 28	543.9 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 7	5.0 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	5.0 Titers
Control Group	Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	31.0 Titers

Secondary

Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which consisted of all subjects who had serologic results available at the antibody persistence time point.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	19.6 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	17.6 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	9.9 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	13.1 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	22.9 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	17.5 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	17.6 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	9.0 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	20.5 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	18.5 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	22.4 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	9.4 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	24.3 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	19.0 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	33.3 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	8.7 Titers
Control Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	10.9 Titers
Control Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	17.8 Titers
Control Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	16.2 Titers
Control Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	12.0 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	81.5 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	38.0 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	55.4 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	100.2 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	82.5 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	65.3 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	31.2 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	108.0 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	59.7 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	42.1 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	42.5 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	21.9 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 24	22.9 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 6	47.3 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 12	64.7 Titers
GSK1562902A AD Approved F Primed Group	Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Month 18	55.3 Titers

Secondary

Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005.

Time frame: At Months 6, 12, 18 and 24

Population: The analysis was performed on the ATP cohort for persistence, which included all subjects who had serologic results available at the antibody persistence time-point.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 6	1422.2 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 12	557.6 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 18	767.5 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 24	503.2 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 24	201.6 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 6	502.3 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 18	278.5 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 12	180.7 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 24	295.4 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 12	274.4 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 18	569.9 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain	A/Indonesia/05/2005, Month 6	751.3 Titers

Secondary

Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain

Titers were presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:28. The flu strain assessed was A/Indonesia/05/2005. No subject from GSK1562902A AD F1 Primed Group has received a second vaccination.

Time frame: At Days 0, 21 (post-vaccination one) and 42 (post-vaccination two)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	933.1 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	47.0 Titers
GSK1562902A AD F1 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	692.4 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	3708.9 Titers
GSK1562902A AD F2 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	157.8 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 42	1606.4 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 0	19.9 Titers
GSK1562902A AD F3 Primed Group	Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain	A/Indonesia/05/2005, Day 21	307.3 Titers

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroprotected Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Number of Subjects With Serious Adverse Events (SAEs)

Seroconversion Factor (SCF) for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines

Frequency of Antigen-specific CD4/CD8 T-cells (Per 10E6) in Tests Identified as Producing at Least Two Out of Four Different Cytokines

Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroconverted (SCR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroconverted (SCR) Subjects for Neutralizing HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Number of Seroprotected (SPR) Subjects for HI Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Seroconversion Factor (SCF) for H5N1 Haemagglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers for Serum H5N1 Haemaglutinin-inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain

Titers for Serum H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain

Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Stain

Titers for Serum Neutralizing HI Antibodies Against A/Indonesia/05/2005 Strain